相关实验视频

Updated: Jul 24, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

新兴的小分子抑制剂作为高风险急性髓性白血病的向治疗方法

Kieran D Sahasrabudhe¹, Mary Albrethsen¹, Alice S Mims¹

¹Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Expert review of hematology

|July 5, 2023

概括

针对性疗法对高风险的急性髓性白血病 (AML) 亚组,包括TP53突变和FLT3突变的AML有希望. 需要进一步的研究来优化这些新的治疗方法,以获得更好的患者结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 是具有侵略性的,在使用传统化疗的高风险亚群中生存率较低.
老年患者和具有特定突变的患者往往因治疗不耐受和低于最佳反应而表现更差.

研究的目的:

审查针对性疗法,特别是小分子抑制剂,针对不同的高风险AML子集.
要突出治疗TP53突变,KMT2A重组,FLT3突变和二次AML的最新进展.

主要方法:

对高风险AML中小分子抑制剂的当前研究的综述.
专注于AML的特定分子和细胞遗传子集.

主要成果:

几种小分子抑制剂在治疗高风险AML亚组方面表现有前途.
向治疗为强化化疗提供了潜在的替代方案.

结论:

小分子抑制剂显示出改善高风险AML的结果的潜力.
持续的研究和更长的随访对于优化这些向疗法至关重要.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.FLT3 FLT3 在线播放在 KMT2A 中.这就是TP53的特点.小分子抑制剂小分子抑制剂有针对性的治疗方法.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...